{"id":"W4324136849","doi":"10.1200/jco.2023.41.6_suppl.tps582","title":"Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—Trial in progress.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Astellas Pharma; Seagen","keywords":"Medicine; Bladder cancer; Cystectomy; Tolerability; Pembrolizumab; Oncology; Internal medicine; Chemotherapy; Carcinoma in situ; Urology; Cancer; Adverse effect; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001635274,0.001319459,0.001310764,0.0003314963,0.0003520298,0.001179194,0.001147032,0.002016349,0.01170275],"category_scores_gemma":[0.001352122,0.0004783607,0.002056316,0.0003477134,0.0004852525,0.0009830821,0.0003963358,0.004052317,0.002127574],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007641682,"about_ca_system_score_gemma":0.00134105,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001148085,"about_ca_topic_score_gemma":0.003589666,"domain_scores_codex":[0.9996866,0.0001689451,0.00001183021,0.00003871164,0.00003444464,0.00005952437],"domain_scores_gemma":[0.9994616,0.0001087953,0.0001307812,0.00003625282,0.0000451239,0.0002174182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6470426,0.02705944,0.004687681,0.005296107,0.003534545,0.0004307197,0.0003530289,0.003117579,0.02008406,0.001980599,0.04155451,0.2448591],"study_design_scores_gemma":[0.7919205,0.1764161,0.006464738,0.0004862587,0.0009193741,0.0004519114,0.0001011733,0.00136178,0.001639512,0.001005945,0.0191857,0.00004699796],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8938323,0.03561443,0.003580489,0.008364758,0.002124658,0.01173441,0.01975105,0.001031766,0.02396613],"genre_scores_gemma":[0.8880564,0.0238894,0.007420242,0.01251708,0.001027288,0.01273399,0.02360888,0.0002565939,0.03049014],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01170275,"threshold_uncertainty_score":0.03914958,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1589544761568458,"score_gpt":0.5099200195524446,"score_spread":0.3509655433955988,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}